Exelixis Inc
EXEL38.225USD
-1.205-3.06%
Close 10/29, 16:00（ET）Quotes delayed by 15 min
10.33BMarket Cap
17.14P/E TTM
More Details of Exelixis Inc Company
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Exelixis Inc Info
Ticker SymbolEXEL
Company nameExelixis Inc
IPO dateApr 11, 2000
CEODr. Michael M. Morrissey, Ph.D.
Number of employees1147
Security typeOrdinary Share
Fiscal year-endApr 11
Address1851 Harbor Bay Parkway
CityALAMEDA
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94502
Phone16508377000
Websitehttps://www.exelixis.com/
Ticker SymbolEXEL
IPO dateApr 11, 2000
CEODr. Michael M. Morrissey, Ph.D.
Company Executives of Exelixis Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.27M
-4.42%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.27M
+0.78%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
258.52K
-25.63%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
159.99K
+6.53%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
81.98K
+13.60%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
10.57K
+1285.98%
Mr. Robert Lee (Bob) Oliver, Jr.
Mr. Robert Lee (Bob) Oliver, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.27M
-4.42%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.27M
+0.78%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
258.52K
-25.63%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
CABOMETYX
517.89M
91.14%
License revenues
49.30M
8.68%
COMETRIQ
2.12M
0.37%
Collaboration services revenues
-1.05M
-0.19%
By RegionUSD
Name
Revenue
Proportion
U.S
524.77M
92.35%
Europe
37.03M
6.52%
Japan
6.46M
1.14%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
CABOMETYX
517.89M
91.14%
License revenues
49.30M
8.68%
COMETRIQ
2.12M
0.37%
Collaboration services revenues
-1.05M
-0.19%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.18%
BlackRock Institutional Trust Company, N.A.
9.45%
Farallon Capital Management, L.L.C.
5.96%
Renaissance Technologies LLC
5.88%
State Street Investment Management (US)
4.23%
Other
64.31%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.18%
BlackRock Institutional Trust Company, N.A.
9.45%
Farallon Capital Management, L.L.C.
5.96%
Renaissance Technologies LLC
5.88%
State Street Investment Management (US)
4.23%
Other
64.31%
Shareholder Types
Shareholders
Proportion
Investment Advisor
44.82%
Investment Advisor/Hedge Fund
28.58%
Hedge Fund
15.52%
Research Firm
2.90%
Pension Fund
2.72%
Individual Investor
2.25%
Sovereign Wealth Fund
1.25%
Bank and Trust
0.58%
Family Office
0.19%
Other
1.20%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1092
260.88M
96.91%
-7.90M
2025Q2
1066
261.07M
96.97%
-18.39M
2025Q1
1059
268.29M
98.20%
-10.58M
2024Q4
992
262.76M
93.66%
-11.36M
2024Q3
924
259.58M
90.96%
-10.18M
2024Q2
908
255.61M
87.75%
-22.29M
2024Q1
905
264.69M
87.26%
-20.82M
2023Q4
882
270.85M
87.07%
-16.64M
2023Q3
847
278.02M
87.32%
-18.15M
2023Q2
833
285.95M
87.85%
-21.34M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
27.41M
10.18%
-1.20M
-4.20%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
25.44M
9.45%
-1.05M
-3.97%
Jun 30, 2025
Farallon Capital Management, L.L.C.
16.04M
5.96%
-2.60M
-13.95%
Jun 30, 2025
Renaissance Technologies LLC
15.82M
5.88%
+995.50K
+6.72%
Jun 30, 2025
State Street Investment Management (US)
11.38M
4.23%
-404.95K
-3.43%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
8.78M
3.26%
+980.50K
+12.58%
Jun 30, 2025
LSV Asset Management
7.82M
2.9%
-340.89K
-4.18%
Jun 30, 2025
AQR Capital Management, LLC
7.61M
2.83%
+712.19K
+10.33%
Jun 30, 2025
Geode Capital Management, L.L.C.
7.45M
2.77%
+28.29K
+0.38%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
5.26M
1.95%
+1.58M
+42.93%
Jun 30, 2025
View more
Related ETFs
Updated: Mon, Oct 6
Updated: Mon, Oct 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
3.48%
Invesco Dorsey Wright Healthcare Momentum ETF
3.09%
Tema Oncology ETF
2.99%
First Trust NYSE Arca Biotechnology Index Fund
2.7%
Invesco Biotechnology & Genome ETF
2.24%
SPDR S&P Biotech ETF
2.1%
First Trust NASDAQ Pharmaceuticals ETF
1.92%
Inspire Faithward Mid Cap Momentum ETF
1.84%
AAM Sawgrass US Large Cap Quality Growth ETF
1.83%
First Trust Health Care Alphadex Fund
1.82%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion3.48%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion3.09%
Tema Oncology ETF
Proportion2.99%
First Trust NYSE Arca Biotechnology Index Fund
Proportion2.7%
Invesco Biotechnology & Genome ETF
Proportion2.24%
SPDR S&P Biotech ETF
Proportion2.1%
First Trust NASDAQ Pharmaceuticals ETF
Proportion1.92%
Inspire Faithward Mid Cap Momentum ETF
Proportion1.84%
AAM Sawgrass US Large Cap Quality Growth ETF
Proportion1.83%
First Trust Health Care Alphadex Fund
Proportion1.82%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
